Duloxetine Capsule, Delayed Release
Product Images NDC 71335-3163

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-3163). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

Chemical structure of duloxetine hydrochloride, showing a naphthalene ring connected to a thienyl group with an ether and amine functional groups.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

A Kaplan-Meier curve showing the proportion of patients with relapse over time (in days) comparing Duloxetine treatment to placebo. The y-axis represents the proportion of relapse, and the x-axis shows time from randomization to relapse. Duloxetine shows a lower relapse proportion than placebo over the study period.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time (days) between Duloxetine and placebo treatment groups. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. Separate curves indicate a higher relapse proportion for placebo compared to Duloxetine.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo groups. The x-axis represents percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 90%. Four lines correspond to the four groups, illustrating comparative effectiveness in pain improvement.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo, each represented by different markers. The y-axis shows percentage of patients improved (0-100), and the x-axis shows percent improvement in pain from baseline (0-100%).*

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Three curves compare Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating patient response rates across various improvement thresholds.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two different datasets), and placebo, illustrating patient response to different dosages over various levels of pain improvement.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The graph compares duloxetine 60 mg once daily versus placebo, plotting percent improvement in pain from baseline on the x-axis against the percentage of patients improved on the y-axis. Duloxetine shows higher percentages of patients improved across pain relief levels compared to placebo.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare placebo and Duloxetine 60/120 mg once daily, with Duloxetine consistently showing higher patient improvement percentages at various pain improvement levels.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

A line chart comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows ranges of percent improvement from >0 to 100, and the y-axis indicates the percentage of patients improved from 0 to 100%. Two lines represent placebo and Duloxetine, showing higher improvement percentages for Duloxetine at most intervals.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The graph shows two curves: one for placebo and one for Duloxetine, illustrating patient improvement across various pain reduction percentages.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

Duloxetine 60 mg delayed-release capsules in a blister pack distributed by Bryant Ranch Prepack. The image shows a strip containing 10 white capsules with black printed markings arranged in two columns.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine 60 mg delayed release oral capsules in a blister pack showing 10 capsules. The capsules are filled with two-tone beads and labeled under Bryant Ranch Prepack. The packaging is designed for prescription use and contains a single blister card.*

FDA Label Image

Label (Lbl713353163)

Label for Duloxetine Delayed-Release Capsules USP 60 mg by Bryant Ranch Prepack. The label includes NDC 71335-3163-1, indicates it contains 30 capsules, and states repackaging by Bryant Ranch Prepack and manufacturing by Lupin Limited. Storage instructions and QR codes for package insert and dosage information are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.